Abstract
The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Current Cancer Drug Targets
Title: Current Treatment Concepts of CML
Volume: 11 Issue: 1
Author(s): A. A. Leitner, A. Hochhaus and M. C. Muller
Affiliation:
Keywords: Chronic myeloid leukemia, imatinib, dasatinib, nilotinib, BCR-ABL, mutation, rare disease, diagnosis, lymphoblastic, fatigue, weight loss, abdominal discomfort, splenomegaly, myeloproliferative neoplasm (MPN), polycythemia vera, thrombocythemia, Leukemia Virus, hematopoietic cells, blood counts, complete hematologic remission (CHR), malignant cells, histologic, cytologic, White blood cell count, fluorescence, hybridization (FISH), metaphases, Plasma Leve, intestinal absorption, metabolism, glycoprotein, hydroxyurea, arsenic, splenectomy, splenic irradiation, busulfan, pregnancy, ribonucleotide, tyrosine kinase inhibitors (TKI), antimetabolite cytarabine, monotherapy, autophosphorylation, bioavailability, phosphate-binding, nucleotide polymorphisms, DOSE, potency, pharmacokinetics, first line therapy, lymphoid, blood-brain barrier, toxicity, Stem Cell Transplantation (SCT), autologous SCT, chemotherapy, diabetes, electrocardiograms
Abstract: The elucidation of the triggering molecular mechanism of chronic myeloid leukemia gave rise to the development of imatinib, a tyrosine kinase inhibitor and a prototype of target-oriented drugs. Imatinib led to impressing response and survival rates and now represents the standard therapy of CML. However, a significant proportion of patients do not tolerate or fail to respond to imatinib treatment. Alternative therapies can be offered to those patients. The particular challenge of CML patient management is to recognize an impending imatinib failure by adequate surveillance and to know about therapeutic options to prevent progression of the disease to accelerated phase or blast crisis since these are more difficult to control. Targeted therapy with second-generation tyrosine kinase inhibitors should be used in synopsis with mutational analysis and the patients history. In this review we present current knowledge of diagnosis, monitoring and therapy strategies of patients with CML.
Export Options
About this article
Cite this article as:
A. Leitner A., Hochhaus A. and C. Muller M., Current Treatment Concepts of CML, Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743637
DOI https://dx.doi.org/10.2174/156800911793743637 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
Current Cancer Drug Targets Generation, Subsets and Functions of Inducible Regulatory T Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Personalized Medicine in a Consumer Age
Current Pharmacogenomics and Personalized Medicine Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Apoptosis in Drug Response
Current Pharmacogenomics New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Synthesis and Evaluation of 2-Substituted Fendiline Analogues as Antileukemics
Letters in Drug Design & Discovery Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry